In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis
The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 102-103
DOI: 10.58347/tml.2026.1757e ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.
Abstract (Originalsprache)
Dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved for several indications, including treatment of chronic rhinosinusitis with nasal polyps, has now been approved for treatment of allergic fungal rhinosinusitis (AFRS) in patients ≥6 years old who previously had sinonasal surgery.1-3 It is the first drug to be approved in the US for this indication.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis. The Medical Letter on Drugs and Therapeutics, 68(1757), 102-103. https://doi.org/10.58347/tml.2026.1757e
Vancouver
In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):102-103. doi:10.58347/tml.2026.1757e
BibTeX
@article{euvimed2026,
title = {In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1757},
pages = {102--103},
doi = {10.58347/tml.2026.1757e}
}
EUVIMED